Wolfgang Koenig Selected Research

Secretory Phospholipases A2

1/2014	Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
11/2013	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.
1/2011	Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.
11/2009	Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.
9/2009	Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
2/2009	Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Koenig Research Topics

Disease

112	Cardiovascular Diseases (Cardiovascular Disease) 05/2024 - 07/2002
112	Inflammation (Inflammations) 01/2024 - 07/2002
71	Coronary Disease (Coronary Heart Disease) 01/2024 - 07/2002
67	Type 2 Diabetes Mellitus (MODY) 01/2024 - 01/2003
62	Myocardial Infarction 01/2024 - 07/2002
45	Atherosclerosis 12/2023 - 04/2002
42	Coronary Artery Disease (Coronary Atherosclerosis) 12/2023 - 07/2002
32	Stroke (Strokes) 12/2023 - 02/2005
25	Hypertension (High Blood Pressure) 05/2023 - 08/2005
24	Acute Coronary Syndrome 11/2023 - 04/2003
22	Insulin Resistance 01/2022 - 10/2006
22	Atherosclerotic Plaque (Atheroma) 12/2021 - 01/2007
19	Obesity 05/2024 - 07/2003
18	Heart Failure 05/2024 - 02/2009
13	Dyslipidemias (Dyslipidemia) 12/2023 - 11/2009
13	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2021 - 11/2003
12	Chronic Renal Insufficiency 11/2023 - 02/2007
12	Prediabetic State (Prediabetes) 01/2021 - 07/2011
10	Diabetes Mellitus 01/2023 - 01/2003
9	Thrombosis (Thrombus) 01/2020 - 03/2009
9	Glucose Intolerance 01/2019 - 12/2005
8	Unstable Angina 10/2018 - 07/2002
8	Neoplasms (Cancer) 10/2017 - 02/2008
7	Chest Pain (Chest Pains) 11/2017 - 03/2009
6	Peripheral Arterial Disease 12/2023 - 07/2014
6	Non-alcoholic Fatty Liver Disease 11/2022 - 10/2009
6	Polyneuropathies (Polyneuropathy) 01/2022 - 01/2015
6	Overweight 11/2021 - 01/2007
5	Hyperlipidemias (Hyperlipidemia) 06/2023 - 11/2008
5	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2023 - 08/2016
5	Abdominal Obesity 01/2022 - 07/2008
5	Kidney Diseases (Kidney Disease) 07/2021 - 11/2009
5	Necrosis 06/2021 - 09/2010
5	Infections 01/2017 - 01/2004

Drug/Important Bio-Agent (IBA)

103	Biomarkers (Surrogate Marker)IBA 05/2024 - 02/2005
83	C-Reactive ProteinIBA 05/2024 - 07/2002
43	LipidsIBA 02/2024 - 07/2002
32	LDL CholesterolIBA 02/2024 - 12/2005
32	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2024 - 11/2002
31	Interleukin-6 (Interleukin 6)IBA 12/2023 - 04/2004
30	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 02/2006
28	HDL CholesterolIBA 10/2023 - 01/2004
25	Fibrinogen (Factor I)FDA Link 12/2023 - 02/2003
24	AdiponectinIBA 12/2023 - 08/2005
22	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2020 - 10/2004
20	oxidized low density lipoproteinIBA 12/2023 - 08/2005
20	CholesterolIBA 09/2023 - 10/2005
17	TroponinIBA 11/2023 - 03/2010
17	CytokinesIBA 11/2023 - 04/2002
16	Proteins (Proteins, Gene)FDA Link 12/2023 - 08/2003
16	Cystatin CIBA 11/2023 - 02/2005
15	Brain Natriuretic Peptide (Natrecor)FDA Link 05/2024 - 04/2010
15	pro-brain natriuretic peptide (1-76)IBA 01/2023 - 12/2006
15	Triglycerides (Triacylglycerol)IBA 01/2023 - 06/2013
14	Troponin T (Troponin T1)IBA 05/2024 - 03/2010
14	Insulin (Novolin)FDA Link 01/2022 - 02/2006
13	Lipoproteins (Lipoprotein)IBA 01/2023 - 05/2003
13	LeptinIBA 01/2022 - 02/2008
12	darapladibIBA 12/2021 - 05/2014
11	ChemokinesIBA 12/2023 - 12/2005
11	CreatinineIBA 11/2022 - 12/2006
11	AdipokinesIBA 01/2022 - 08/2004
11	InterleukinsIBA 06/2021 - 10/2005
10	Lipoprotein(a)IBA 01/2024 - 10/2003
10	Uric Acid (Urate)IBA 09/2022 - 12/2005
9	Troponin IIBA 05/2024 - 08/2016
9	ApolipoproteinsIBA 04/2019 - 10/2003
9	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2013 - 11/2002
8	omega-Chloroacetophenone (Mace)IBA 01/2023 - 07/2008
7	ALN-PCSIBA 05/2024 - 01/2020
7	HDL LipoproteinsIBA 11/2022 - 09/2006
7	Natriuretic PeptidesIBA 11/2021 - 12/2006
7	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 11/2008
7	Vitamin D FDA LinkGeneric 01/2019 - 10/2011
7	Rosuvastatin Calcium (Crestor)FDA Link 05/2012 - 11/2008
7	Chemokine CCL5IBA 01/2011 - 12/2005
6	Blood Proteins (Serum Proteins)IBA 01/2024 - 09/2004
6	UromodulinIBA 01/2022 - 09/2019
6	AlbuminsIBA 12/2021 - 12/2010
6	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2021 - 01/2006
6	Growth Differentiation Factor 15IBA 01/2021 - 01/2016
6	Interleukin-18 (Interleukin 18)IBA 01/2018 - 10/2005
6	EnzymesIBA 05/2014 - 01/2007
6	Secretory Phospholipases A2IBA 01/2014 - 02/2009
5	evolocumabIBA 02/2024 - 06/2016
5	Colchicine FDA LinkGeneric 01/2024 - 12/2019
5	Serum Amyloid A Protein (Serum Amyloid A)IBA 12/2023 - 01/2006
5	Particulate MatterIBA 12/2023 - 03/2009
5	Monoclonal AntibodiesIBA 08/2023 - 01/2017
5	ReninIBA 05/2023 - 01/2016
5	canakinumab FDA Link 10/2022 - 01/2017
5	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2022 - 05/2005
5	25-hydroxyvitamin DIBA 01/2022 - 10/2011
5	Peptides (Polypeptides)IBA 01/2022 - 08/2011
5	hydroxide ionIBA 01/2022 - 01/2013
5	Peroxidase (Myeloperoxidase)IBA 01/2022 - 06/2012
5	PPAR alphaIBA 01/2019 - 04/2002
5	Phospholipases (Phospholipase)IBA 11/2013 - 02/2009

Therapy/Procedure

54	Therapeutics 02/2024 - 07/2002
7	Secondary Prevention 06/2023 - 11/2002